Rockefeller Capital Management L.P. Purchases 12,358 Shares of Zoetis Inc. (NYSE:ZTS)

Rockefeller Capital Management L.P. raised its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 2.8% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 459,729 shares of the company's stock after buying an additional 12,358 shares during the quarter. Rockefeller Capital Management L.P. owned about 0.10% of Zoetis worth $89,785,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in ZTS. Isthmus Partners LLC lifted its position in Zoetis by 1.1% in the 3rd quarter. Isthmus Partners LLC now owns 68,648 shares of the company's stock valued at $13,412,000 after acquiring an additional 760 shares in the last quarter. Hantz Financial Services Inc. raised its stake in shares of Zoetis by 4.4% in the 3rd quarter. Hantz Financial Services Inc. now owns 141,299 shares of the company's stock valued at $27,607,000 after purchasing an additional 5,938 shares during the period. Vinva Investment Management Ltd lifted its holdings in shares of Zoetis by 8.2% in the third quarter. Vinva Investment Management Ltd now owns 19,456 shares of the company's stock valued at $3,790,000 after purchasing an additional 1,467 shares in the last quarter. Financial Counselors Inc. boosted its position in shares of Zoetis by 5.8% during the third quarter. Financial Counselors Inc. now owns 155,696 shares of the company's stock worth $30,420,000 after buying an additional 8,526 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Zoetis by 5.3% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,896,106 shares of the company's stock worth $761,221,000 after buying an additional 194,542 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Zoetis Stock Performance

Zoetis stock traded down $1.49 during midday trading on Friday, reaching $175.25. 1,543,412 shares of the company's stock were exchanged, compared to its average volume of 2,545,742. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $201.92. The stock's 50-day simple moving average is $184.18 and its 200 day simple moving average is $180.78. The firm has a market cap of $79.07 billion, a price-to-earnings ratio of 33.22, a P/E/G ratio of 2.71 and a beta of 0.90.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The business had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.29 billion. During the same quarter last year, the firm posted $1.36 EPS. The company's quarterly revenue was up 11.6% on a year-over-year basis. On average, analysts expect that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be paid a $0.432 dividend. The ex-dividend date of this dividend is Thursday, October 31st. This represents a $1.73 dividend on an annualized basis and a yield of 0.99%. Zoetis's dividend payout ratio (DPR) is currently 32.52%.

Analyst Ratings Changes

ZTS has been the topic of several research reports. Stifel Nicolaus boosted their target price on Zoetis from $200.00 to $210.00 and gave the company a "buy" rating in a research note on Wednesday, September 18th. Piper Sandler increased their target price on shares of Zoetis from $195.00 to $210.00 and gave the stock an "overweight" rating in a report on Wednesday, August 14th. BTIG Research lifted their price target on shares of Zoetis from $220.00 to $225.00 and gave the company a "buy" rating in a research note on Monday, August 12th. Argus upgraded shares of Zoetis to a "strong-buy" rating in a research note on Friday, August 9th. Finally, JPMorgan Chase & Co. raised their price objective on Zoetis from $225.00 to $230.00 and gave the company an "overweight" rating in a report on Friday, October 11th. Ten research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Zoetis has a consensus rating of "Buy" and an average target price of $221.44.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.